Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in patients with type 2 diabetes during NovoMix® 30 treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin, Isophane

Criteria

Inclusion Criteria:

• Any patient with diabetes type 2 diabetes

• Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin

• Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient

Exclusion Criteria:

• Known or suspected allergy to study product(s) or related products

• Pregnancy, breast-feeding or intention of becoming pregnant within the next 6 months